Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
M Yi, X Zheng, M Niu, S Zhu, H Ge, K Wu - Molecular cancer, 2022 - Springer
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …
cells from exhausted status and revive immune response against cancer cells. Based on the …
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management
Abstract Human papillomavirus (HPV)-positive (HPV+) oropharyngeal squamous cell
carcinoma (OPSCC) has one of the most rapidly increasing incidences of any cancer in high …
carcinoma (OPSCC) has one of the most rapidly increasing incidences of any cancer in high …
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
AJ Korman, SC Garrett-Thomson… - Nature Reviews Drug …, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …
discussion and experimentation for over a hundred years. Several successful cancer …
Fundamental mechanisms of immune checkpoint blockade therapy
SC Wei, CR Duffy, JP Allison - Cancer discovery, 2018 - AACR
Immune checkpoint blockade is able to induce durable responses across multiple types of
cancer, which has enabled the oncology community to begin to envision potentially curative …
cancer, which has enabled the oncology community to begin to envision potentially curative …
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …
[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
Delivery technologies for cancer immunotherapy
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Regulatory T cells (Tregs) are abundant in tumor tissues, raising a question of whether
immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or …
immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or …
Tumor-infiltrating lymphocytes in the immunotherapy era
ST Paijens, A Vledder, M de Bruyn… - Cellular & molecular …, 2021 - nature.com
The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …